Over 11,500 participants, both online and in Paris, France, attended EuroPCR 2023, the world-leading course in interventional cardiovascular medicine, from May 16 to 19, 2023. Below is a curated list of key presentation highlights from the EuroPCR 2023.
BIOADAPTOR RCT1: (NCT04192747) Dr. Shigeru Shaito presented key findings from the BIOADAPTOR RCT trial, which studied 445 patients with coronary artery disease (CAD). They were either implanted with the DynamX Bioadaptor® or the Resolute Onyx™ stent. Results showed a 1.8% target lesion failure (TLF) at 12 months for DynamX® compared to 2.8% for Resolute Onyx™, meeting the noninferiority primary endpoint (p<0.001). Interestingly, at 12 months, DynamX® showed a significant benefit in plaque volume regression of -9%, while Resolute Onyx™ had a +10% increase. Further and longer studies are needed to assess the sustained impact of DynamX® beyond 1 year.
ADALA2,3: (NCT05632445) Trial results showed low-dose direct oral anticoagulant (DOAC) apixaban may be preferable to....
Log in to get full access to EuroPCR 2023 conference highlights.
